Home Musculoskeletal Disorders Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD Cell Therapy

Duchenne-muscular-dystrophy-1068x711 — Capricor Therapeutics has found a new partner for its lead pipeline candidate CAP-1002. Capricor is gearing up to study the cell therapy in a pivotal Phase III trial in Duchenne muscular dystrophy (DMD).[Centers for Disease Control and Prevention's Public Health Image Library]

Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD Cell Therapy

Five years after J&J walks away, Nippon Shinyaku joins Capricor in commercializing Duchenne muscular dystrophy candidate CAP-1002

By Alex Philippidis

February 1, 2022

Capricor Therapeutics has found a new partner for its lead pipeline candidate CAP-1002. Capricor is gearing up to study the cell therapy in a pivotal Phase III trial in Duchenne muscular dystrophy (DMD).[Centers for Disease Control and Prevention's Public Health Image Library]

Capricor is gearing up to study the cell therapy in a pivotal Phase III trial in Duchenne muscular dystrophy (DMD). Nippon Shinyaku, which does business in the U.S. through subsidiary NS Pharma, has inked an up-to-$735 million exclusive U.S. commercialization and distribution agreement for CAP-1002 in DMD. Capricor President and CEO Linda Marbán, PhD, told GEN Edge her company first met with representatives of NS Pharma two years ago at the J.P. Morgan 38th Healthcare Conference . . .